Granules India (532482) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 revenue declined 19% year-over-year to ₹9,666 million, mainly due to a voluntary pause in manufacturing and distribution at the Gagillapur facility following a US FDA inspection that resulted in six Form 483 observations; corrective actions and third-party reviews were initiated.

• Manufacturing and dispatches at Gagillapur resumed in late September with a phased restart in October after risk assessment and FDA concurrence.

• New product launches in the US (CNS, ADHD, and Pantoprazole) and Europe, along with expanded capacity at Genome Valley and ongoing R&D investments, are expected to drive near-term growth.

• Unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2024, were approved and released, with no material misstatements identified by statutory auditors.

• Both standalone and consolidated results were reviewed by statutory auditors with no material misstatements identified.

Financial highlights

• Q2 FY25 revenue was ₹9,666 million, down 19% year-over-year and 18% sequentially; standalone revenue was ₹8,519.50 million, and consolidated revenue was ₹11,798.65 million.

• Gross margin improved to 62% from 51.7% year-over-year, driven by a favorable product mix and higher finished dosage sales.

• EBITDA for the quarter was ₹2,033 million (21% of sales), up 313 basis points year-over-year, while PAT fell 5% to ₹972 million.

• Cash flow from operations was ₹2,007 million, up from ₹329 million in Q2 FY24; consolidated net cash from operations for H1 FY25 was ₹4,168.16 million.

• CapEx for the quarter was ₹1,324 million, mainly invested in Granules Life Sciences and CZRO.

Outlook and guidance

• Growth in the near term will be led by new launches from the GPI site in the US and Europe, with a spillover impact from the Gagillapur slowdown expected to lessen in Q3.

• API and PFI demand, especially for paracetamol, is expected to improve in Q3 and normalize by Q4.

• Four additional US launches are planned for the remainder of FY25, with further approvals expected in Q4.

• Focus remains on growing finished dosage sales, new product launches, and expanding in North America and other key markets.

• Manufacturing at the Gagillapur facility resumed in a staggered manner in October 2024.